Amgen (AMGN)
327.66
+2.80 (0.86%)
Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses
The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world.

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.
Via Benzinga · March 10, 2025

Via The Motley Fool · March 7, 2025

Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.
Via StockStory · March 6, 2025

Via Benzinga · March 6, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Via Benzinga · March 3, 2025

Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.
Via Benzinga · February 28, 2025

Via Benzinga · February 26, 2025

Via The Motley Fool · February 25, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?
Via Talk Markets · February 24, 2025

Tariffs could have big impact on earnings in 2025.
Via Talk Markets · February 20, 2025

Via Benzinga · February 11, 2025

Via The Motley Fool · February 10, 2025

Biopharmaceutical company Gilead Sciences (NASDAQGILD)
will be announcing earnings results tomorrow afternoon. Here’s what to expect.
Via StockStory · February 10, 2025

Biotech company Vertex Pharmaceuticals (NASDAQVRTX)
will be reporting results tomorrow afternoon. Here’s what to look for.
Via StockStory · February 9, 2025

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also exist.
Via Stocktwits · February 7, 2025

Via Benzinga · February 6, 2025

Shares of biotech company Amgen (NASDAQAMGN)
jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter, and its full-year revenue guidance came in slightly higher than Wall Street's estimates.
On the other hand, its full-year EPS guidance slightly missed, and its EPS was in line with Wall Street's estimates.
Overall, this quarter was mixed with better-than-anticipated sales but mediocre profitability. The market seemed to focus on the sales, and the stock traded up as a result.
Via StockStory · February 5, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · February 5, 2025